Print on hospital headed paper

PATIENT INFORMATION SHEET
Version 7.0 7th December 2021

PACE (main study and vaccine cohort)

This Patient Information Sheet is for patients who are already enrolled in the PACE study who would also like to take part in the Vaccine Sub-study.

Understanding the risk of infection in Acute Myeloid Leukaemia, including the impact of COVID-19

We would like to invite you to take part in a research study. Joining the study is entirely up to you; before you decide we would like you to understand why the research is being done and what it would involve for you. Please take time to read this information carefully and discuss it with others if you wish.

Part 1 tells you the purpose of this study and what will happen to you if you take part, and Part 2 gives you more detailed information about the conduct of the study. Do ask if anything is unclear, or if you would like more information. Take time to decide whether or not you wish to take part.

If you choose not to take part, this will not affect the care you get from your own doctors.

Thank you for reading this information sheet.

Contents **Page**

Part 1 – Main Information Sheet

1 What is the purpose of this study?

The most common form of acute leukaemia in adults is called Acute Myeloid Leukaemia (AML). Infection is a common problem in patients with AML because both the underlying disease and the chemotherapy treatment can make it harder for the body to fight off infections (because they both reduce the body's immune system and white blood cells needed to fight infection). The Coronavirus pandemic (COVID-19) is now having major implications on healthcare globally. More information is required to understand how best to treat patients with AML who develop COVID-19, especially as they are already at risk of developing infections due to their disease.

This study is aimed at collecting information on the number and severity of all infections in patients with AML, including those who have recovered from prior COVID-19 infection or who subsequently develop COVID-19. We would also like to collect information about immune responses to the COVID-19 vaccine in patients with AML. This information will be essential to understanding how to manage infections in AML patients in the future, and whether COVID-19 vaccines can generate sufficient immune responses in AML patients to provide sustained immunity.

2 Why have I been invited to take part?

Your doctor has invited you to consider taking part because you have been diagnosed with AML or a form of pre-leukaemia called MDS-EB2 and are either about to start treatment, already receiving treatment for your disease or your AML has come back.

200 patients from across the UK will be entering this study over a period of 6 months. If you take part in this study we will collect information on you for a minimum of 6 months and up to 24 months.

3 How do I enter the study?

The first step is to decide whether you want to take part in the study. Your doctor or nurse will describe the study and talk through this information sheet with you. This information sheet is yours to take away. If you choose to enter the study, you will be invited to sign an Informed Consent Form to show that you understand what is involved when taking part in this study.

The original signed Informed Consent Form will be placed in your hospital notes and a copy will be given to you for your records.

4 Do I have to take part?

No, participation in this study is entirely voluntary. If you consent to participate, you are still free to withdraw from the study at any time without giving a reason. If you decide not to take part, your treatment and standard of care will not be affected in any way. For more information see the section "What will happen if I don't want to carry on with the study?"

5 What will happen to me if I take part?

Consent
If you decide to take part in this study, we will ask you to give your written informed consent to take part.

What will happen during the study?

During the study we will collect information about your medical history, demographic data and details of some of the assessments you may receive, or may have already received, as part of your standard care. You will not be asked to have any additional assessments as a result of taking part in this study. We will collect the following information from the time you enter the study for up to 24 months.

- Demographic data (age, sex, ethnicity)
- Medical history (pre-existing conditions, previous chemotherapy)
- Disease status (newly diagnosed, relapsed) and changes during the study
- Performance status (a measurement of how your disease impacts your daily living abilities)
- Height and weight
- COVID-19 status
- Treatment plan for AML (intensive chemotherapy, non-intensive chemotherapy)
- Infections you experience
- Admissions to hospital
- Date(s) of COVID-19 vaccination

What samples will be collected?

Samples will be collected for the Sampling Sub-study and from patients in the Vaccine Cohort. Both the Sampling Sub-study and Vaccine Cohort are optional. The optional Sampling sub study aims to study the immune responses to infection, including COVID-19 infection. The Vaccine Cohort aims to collect information on the immune response produced by COVID-19 vaccines.

a) Samples collected for the optional sampling sub-study

If your hospital is participating in the optional sampling sub-study, we would like to collect samples at different time points during your treatment. This sub-study is optional and you may still take part in the main study if you do not agree to us collecting your samples.

We would like to collect blood, stool, salvia and sputum samples. These will be sent to the laboratory at the Royal Free hospital in London for analysis. The aim of the analysis will be to investigate immune responses to infections including COVID-19 and the role of the respiratory and gastrointestinal systems in this. The Royal Free Hospital or your local hospital will process your blood sample to separate out the serum and RNA (ribonucleic acid; a type of genetic material) to study the immune system's response to infection.

If you are on an intensive chemotherapy regimen and you agree to participate in the sub-study, samples will be collected around the time you enter the study and monthly for 6 months from

the time you enter the study. If you are on a non-intensive chemotherapy regimen, samples would only be taken at the time of study entry, if you are admitted to hospital with an infection, and on recovery (4 weeks later).
Regardless of the chemotherapy regimen you are on, if you are diagnosed with COVID-19, further samples will also be collected each week for up to 4 weeks.

Blood Samples
If you consent to the Sampling sub-study, we will ask to collect additional blood samples. If possible, these will be taken at the same time as you have routine blood tests. The amount of blood taken will be between 1 and 6 teaspoons (5 - 30ml).

Stool, saliva and sputum samples
These will be requested monthly from when you start the Sampling sub-study, again if you are admitted to hospital with an infection, and on recovery (4 weeks later). If you are diagnosed with Covid-19, we will ask for weekly saliva and sputum samples for 4 weeks. To provide a saliva sample, you will be asked to spit into a small sterile plastic tub. To provide a sputum sample, your healthcare professional will ask you to take several deep breaths before giving a deep cough to bring up the sputum.

b) Samples collected for the optional Vaccine Cohort

If your hospital is participating in the optional Vaccine Cohort, we would like to collect samples following your COVID-19 vaccinations. This cohort is optional and you may still take part in the main study if you do not agree to us collecting samples for this study.

We would like to collect blood samples 4 weeks after your first, second, third and fourth COVID-19 vaccines (where possible) and 6 months after your second vaccine (or just before your third vaccine if this is sooner or more practical). If possible, these will be taken at the same time as you have routine blood tests. The amount taken will be 5 teaspoons (25mls). Your blood samples will be analysed at The Royal Free Hospital in London, and at Oxford Immunotec Ltd. Scientists at The Royal Free Hospital will test whether your blood has antibodies to COVID-19 after your vaccine, and whether components of your blood are able to neutralise COVID-19 once you are vaccinated. At Oxford Immunotec, scientists will calculate how many of your T-cells (cells in your blood that respond to an infection) have been activated by your COVID-19 vaccination.

If you have provided blood samples for the PACE Sampling sub-study, and only with your consent, we would also like to further analyse these stored samples to test the immune response to your first vaccine. The scientists at the Royal Free Hospital will test whether these stored blood samples contain antibodies to COVID-19, and whether components in these blood samples can neutralise COVID-19 virus. Scientists at Oxford Immunotec Ltd, will test whether these stored blood samples contains T-cells that have been activated by the COVID-19 vaccine.

Will any genetic tests be done?

The Royal Free Hospital will be studying the RNA taken from the blood samples collected from patients participating in the Sampling sub-study and those in the Vaccine Cohort. These types of tests will determine which genes have been activated because of an infection, including infection with Covid-19.

What will happen to the samples collected during the study?

Any samples collected during the study may be stored for further research. Any further research carried out on the samples will need to have ethical approval.

6 What will happen if I don't want to carry on with the study?

You are free to withdraw from this study at any time, you do not have to give a reason and your future care will not be affected. If you choose to withdraw from the study, we would still retain and analyse any information or samples we have collected up until withdrawal.

7 What are the possible benefits of taking part?

There is no direct benefit to you for taking part in this study. The information gained from this study may help to improve the care of AML patients in the future.

8 What are the possible risks of taking part?

This study will collect information about any infections you experience during your treatment for AML. For the main observational study, there are no additional clinical assessments or visits above your standard of care which could result in increased risks. If you decide to participate in the Sampling sub-study or Vaccine Cohort, the additional risks are as follows:

Blood Sampling:
Having blood taken may cause some discomfort, bleeding or bruising where the needle enters the body and, in rare cases, light-headedness and fainting.

Sputum sampling (Sampling sub-study only):
When you aren't feeling well, the deep coughing associated with providing a sputum sample may feel uncomfortable. You may experience some chest discomfort after giving the sample.

Part 2 – Additional Information

1 Will I be paid to take part?

You will not receive any money for taking part in this study. No additional visits to hospital are required above your standard of care visits.

2 What to do if there are problems

If you have a concern about any aspect of this study, you should ask to speak to your doctor or study nurse who will do their best to answer your questions.

Complaints
If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints Procedure. Details can be obtained from your hospital. Additionally, the contact information for your local Patient Advice and Liaison Service (PALS) or equivalent is at the end of this information sheet.

If you are harmed
If you are harmed by taking part in this study there are no special compensation arrangements. If you are harmed due to someone's negligence, then you may have grounds for a legal action for compensation but you may have to pay your legal costs. NHS Trusts have a duty of care to participants whether or not the participant is taking part in a study and normal National Health Service complaints mechanisms will still be available to you. If you have private medical insurance, you should tell your insurer that you are taking part in research. They will let you know if it affects your policy.

3 What if relevant new information becomes available?

If we get new information concerning the study that is applicable to you, your doctor will discuss this with you. If you decide to continue in the study your doctor may ask you to sign an updated Informed Consent Form.

4 Will my taking part in the study be kept confidential?

All information collected about you for this study will be subject to the General Data Protection Regulation and Data Protection Act 2018 and will be kept strictly confidential.

All information collected by the Sponsor (the University of Birmingham) will be securely stored at the Study Office at the Cancer Research UK Clinical Trials Unit, University of Birmingham on paper and electronically and will only be accessible by authorised personnel associated with the study. The only people in the University of Birmingham who will have access to information that identifies you will be people who manage the study or audit the data collection process. When you are entered into the study we will collect your date of birth. You will be given a unique study number and in routine communication between your hospital and the Study Office, you will only be identified by this study number. A copy of your signed consent form may be reviewed by staff from the Study Office during an audit to ensure that the correct consenting procedure has been carried out. This will have your name and signature on it.

The NHS may use your name and contact details to contact you about the research study, and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study.

Study documents including identifiable data will be stored during the study and for at least 10 years after the end of study in a specialist archive facility with any access strictly controlled. This will allow the data to be re-examined if any questions are raised over the study results. After 10 years the storage of this data will be reviewed.

Samples taken for research purposes and sent to the Royal Free Hospital or to Oxford Immunotec Ltd will only be identified by your unique study number and date of birth. This information is the minimum needed to make sure that your samples can be correctly matched to your clinical data held by the University of Birmingham.

In addition anonymised data from the study may be provided to other 3rd parties (e.g. pharmaceutical companies or other academic institutions) for research or safety monitoring. These organisations could be within Europe, or outside Europe where the data protection laws may be different. Data sent abroad will not allow you as an individual to be identified.

By taking part in the study, you will be agreeing to allow research staff from the Study Office at the University of Birmingham to look at the study records, including your medical records. It may be necessary to allow authorised personnel from government regulatory agencies, the Sponsor and/or NHS bodies to have access to your medical and research records. This is to ensure that the study is being conducted to the highest possible standards.

From time to time we may be asked to share the study information (data) we have collected with researchers running other studies in this organisation and in other organisations so that they can perform analysis on the data to answer other important questions about AML. These organisations may be universities, NHS organisations or companies involved in health research and may be in this country or abroad. Any such request is carefully considered by the study researchers and will only be granted if the necessary procedures and approvals are in place. This information will not identify you and will not be combined with other information in a way that could identify you. The information will only be used for the purpose of health research, and cannot be used to contact you or to affect your care. It will not be used to make decisions about future services available to you, such as insurance. Under no circumstances will you be identified in any way in any report, presentation or publication arising from this or any other study.

For further information about how health researchers use your information please go to: https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/data-protection-and-information-governance/gdpr-guidance/templates/template-wording-for-generic-information-document/

You can withdraw your consent to our processing of your data at any time. Under the provisions of the General Data Protection Regulation (GDPR) 2018, you have the right to know what information the Study Office has recorded about you. If you wish to view this information, or find more about how we use this information, please contact Legal Services at the address below.

Legal Services

University of Birmingham

Edgbaston

Birmingham, B15 2TT

5 What will happen to the results of the study?

When the study is complete the results will be published in a medical journal but no individual patients will be identified. If you would like to have a copy of the published results, please ask your doctor or nurse.

6 Who is organising and funding the study?

This research is being funded by the charities Cure Leukaemia and Blood Cancer UK, in addition to an educational grant from Celgene. The study is being run by the Trials Acceleration Programme (TAP) hub at the Cancer Research UK Clinical Trials Unit at the University of Birmingham.

7 Who has reviewed the study?

This research study has been reviewed by the Cancer Research UK Clinical Trials Unit and also by an independent Research Ethics Committee. Research Ethics Committees review all research to protect the safety, rights, wellbeing, and dignity of participants. This study was reviewed and received favourable opinion by North of Scotland (1) Research Ethics Committee. It has also been reviewed by the national Health Research Authority.

8 Further information and contact details

If you have any questions or concerns about your disease or this research study, please discuss them with your doctor. You may also find it helpful to contact the following organisations:

<< insert name and contact telephone number of Principal Investigator >>

<< insert name and contact telephone number of Research Nurse >>

<< insert 24 hour emergency contact details >>

<<Delete as appropriate for your site>>

You may also find it helpful to contact the following organisations:

England

Your local Patient Advice and Liaison Service (PALs) or equivalent who provide advice and support to patients, their families and their carers, website:
http://www.nhs.uk/chq/Pages/1082.aspx?CategoryID=68&SubCategoryID=153
Or local PALS details where available:
<< insert address and contact telephone number of local service >>

Northern Ireland

In Northern Ireland the Patient Client Council (PCC) can provide assistance and support at any stage of the health and social care services complaints procedure. The PCC is an independent body who represent the views of the public in all areas of health and social care. They can also assist you to make a complaint. This is a confidential and free service.
http://www.patientclientcouncil.hscni.net/
Telephone: 0800 917 0222
Email: info.pcc@hscni.net

Scotland

The Patient Advice and Support Service is an independent service which provides free, accessible and confidential information, advice and support to patients, their carers, and families about NHS healthcare in Scotland.

http://www.patientadvicescotland.org.uk/

Wales

Community Health Councils (CHCs) are independent bodies, set up by law, who listen to what individuals and the community have to say about the health services with regard to quality, quantity, access to and appropriateness of the services provided for them. CHCs can also help, advise and support people who wish to make complaints about NHS services and similar matters. This advice is completely free, independent and confidential.

http://www.wales.nhs.uk/sitesplus/899/home

Sources of information

CancerHelp: an information service about cancer from Cancer Research UK, Freephone 0808 800 40 40, www.cancerhelp.org.uk

Macmillan Cancer Support: Freephone 0808 800 0000, www.macmillan.org.uk

Blood Cancer UK helpline: Freephone 0808 2080 888, www.bloodcancer.org.uk

Please take as much time as you need to make a decision and then let your doctor or nurse know what you have decided.

Thank you for taking time to read this leaflet and considering taking part in this study.